Description
An NSAID and COX-1 and COX-2 inhibitor (IC50s = 2.6 and 1.53 µM, respectively); inhibits NF-κB transactivation in a reporter assay using Jurkat T cells (IC50 = 61.7 µM); reduces aggregation in platelet-rich plasma and washed isolated human platelets (IC50s = 88 and 0.6 µM, respectively); decreases fMLP-induced superoxide formation and β-glucuronidase release, as well as calcimycin-induced LTB4 formation, in human PMN cells (IC50s = 0.50, 0.53, and 0.14 µM, respectively); increases the latency to withdraw for hot plate and tail-flick tests in mice (ED50s = 64 and 54 mg/kg, respectively), as well as reduces paw swelling in a mouse model of carrageenan-induced paw edema (ED50 = 57 mg/kg)